(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 March 2006 (09.03.2006)

PCT

(10) International Publication Number
WO 2006/026703 A3

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61K 31/497* (2006.01)
C07D 403/14 (2006.01) *A61K 31/437* (2006.01)
A61K 47/22 (2006.01)

(21) International Application Number:
PCT/US2005/031099

(22) International Filing Date: 31 August 2005 (31.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/606,742 2 September 2004 (02.09.2004) US
60/610,765 17 September 2004 (17.09.2004) US

(71) Applicant *(for all designated States except US)*: **SMITHKLINE BEECHAM CORPORATION** [US/US]; One Franklin Plaza, PO Box 7929, Philadelphia, PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GUDMUNDSSON, Kristjan** [IS/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Dept, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **BOGGS, Sharon, Davis** [US/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Dept, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(74) Agents: **DADSWELL, Charles, E** et al.; c/o GlaxoSmithKline, Corporate Intellectual Property Dept, Five Moore Drive, PO Box 13398, Research Trangle Park, NC 27709 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
5 October 2006

(15) Information about Correction:
Previous Correction:
see PCT Gazette No. 21/2006 of 26 May 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS

(57) Abstract: The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind specifically to the chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 and/or CCR5 of a target cell.

WO 2006/026703 A3